OverviewSuggest Edit

Verve Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. It develops medicines to edit the genome of adults that mimic naturally occurring gene variants to lower LDL cholesterol and triglyceride levels. Its products can be used for the treatment of coronary artery and cardiovascular diseases.

TypePublic
Founded2018
HQCambridge, MA, US
Websitevervetx.com

Latest Updates

Employees (est.) (May 2021)70
Job Openings15
Share Price (Sept 2021)$47.8
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Verve Therapeutics

Burt Adelman

Burt Adelman

Co-Founder and Chairman of the Board
J. Keith Joung

J. Keith Joung

Co-Founder
Anthony Philippakis

Anthony Philippakis

Co-Founder, Board Member
Sekar Kathiresan

Sekar Kathiresan

Co-Founder, Chief Executive Officer and Board Member
Barry Ticho

Barry Ticho

Co-Founder
Issi Rozen

Issi Rozen

Co-Founder and Strategic Advisor
Show more

Verve Therapeutics Office Locations

Verve Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
NE47, 500 Technology Square #901
Show all (1)

Verve Therapeutics Financials and Metrics

Verve Therapeutics Revenue

Market capitalization (29-Sept-2021)

2.2b

Closing stock price (29-Sept-2021)

47.8
Verve Therapeutics's current market capitalization is $2.2 b.
Show all financial metrics

Verve Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Verve Therapeutics Online and Social Media Presence

Embed Graph

Verve Therapeutics News and Updates

Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Belli…

Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease

Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol

Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new in vivo data from the company’s proprietary lipid nanoparticle (LNP) delivery te…

Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021

Verve Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced initial public offering of 16,…

Verve Therapeutics stock soars 68% in trading debut

Verve Therapeutics stock soars 68% in trading debut
Show more

Verve Therapeutics Frequently Asked Questions

  • When was Verve Therapeutics founded?

    Verve Therapeutics was founded in 2018.

  • Who are Verve Therapeutics key executives?

    Verve Therapeutics's key executives are Burt Adelman, J. Keith Joung and Anthony Philippakis.

  • How many employees does Verve Therapeutics have?

    Verve Therapeutics has 70 employees.

  • Who are Verve Therapeutics competitors?

    Competitors of Verve Therapeutics include AXON Neuroscience, Mesoblast and OmniSeq.

  • Where is Verve Therapeutics headquarters?

    Verve Therapeutics headquarters is located at NE47, 500 Technology Square #901, Cambridge.

  • Where are Verve Therapeutics offices?

    Verve Therapeutics has an office in Cambridge.

  • How many offices does Verve Therapeutics have?

    Verve Therapeutics has 1 office.